Ranibizumab Treatment for Retinal Vein Occlusion

N/AUnknownNCT01968616

Kyoto University, Graduate School of Medicine100 enrolled

Overview

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Macular Edema Due to BRVO/CRVO

Interventions

Ranibizumab, 0.5mg, IntravitrealDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent form * Male or female of aged 18 years or older * Macula edema secondary to BRVO/CRVO * Decrease of VA due to macular edema Exclusion Criteria: * Prior episode of RVO * Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye) * Ocular disorders in the study eye that may confound interpretation of study results * History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO * The pregnant or lactating woman

Locations (1)

Department of Ophthalmology, Kyoto University Hospital

Kyoto, Kyoto, Japan

RECRUITING

Outcomes

Primary Outcomes

Mean foveal thickness measured by SD-OCT

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.